2016 update from RBWH Nuclear Medicine

The Department of Nuclear Medicine, RBWH, has approval, and is in the planning stage, for an expansion of our TGA licensed Radiopharmaceutical laboratory that supplies PET tracers to a number of PET facilities in Queensland. This expansion includes a new Clean Room for sterile manufacture, additional hot cells and synthesis modules.

In 2016 we added 68Ga-Dotatate and 68Ga-PSMA-HBED to FDG to the compounds we distribute to other hospitals, as well as supporting a substantial increase of the in-house demand. A number of new tracers also came online for clinical and research use, including 18F-GE-180 (neuroinflammation), 18F-GE216 (Alzheimer’s disease), nucleophilic 18F-DOPA, 68Ga-pentixafor (overexpression of CXCR4 receptors).

Our State-wide 177Lu-TATE therapy service expanded by 50%, increasing the availability of radionuclide therapy to patients suffering neuroendocrine tumours. This coupled with production of 177Lu-PSMA617 for prostate therapy should lead to a very exciting 2017.

Our Research Radiochemist, Melissa Latter (pictured), won a very prestigious Churchill Fellowship. She will be visiting overseas centres to gather expertise which will allow us to establish a premier manufacturing and training site for translational radiopharmaceutical science. We also have 4 staff starting on their TEAP journey; Soren Lummis and Dominique Scott in Radiopharmaceutical Science and Orrie Dancewicz and Shaun Patford in the DIMP program.

GCUH Medical Imaging Tour

The attendees of the 14th PRIMPS meeting had the opportunity to have a tour of the new medical imaging facilities at the Gold Coast University Hospital (GCUH). If you missed it – here are photos of some of the things we got to see (and the GCUH being constructed).

Thanks to Timothy Ireland for the photos (and the tour).